Marijuana-derived drug for epilepsy gets FDA committee recommendation

A US Food and Drug Administration advisory committee on Thursday unanimously ...

Posted: Apr 19, 2018 6:44 PM
Updated: Apr 19, 2018 6:44 PM

A US Food and Drug Administration advisory committee on Thursday unanimously recommended approval of an epilepsy drug that would be the first plant-derived cannabidiol medicine for prescription use in the United States.

The FDA will vote in June whether to approve the drug, Epidiolex, an oral solution, for the treatment of severe forms of epilepsy in a small group of patients. The FDA has approved synthetic versions of some cannabinoid chemicals found in the marijuana plant for other purposes, including cancer pain relief.

Epidiolex is an oral solution of marijuana plant-derived cannabidiol

If approved by the FDA, the medicine will treat severe epilepsy syndromes

Cannabidiol, also called CBD, is one of more than 80 active cannabinoid chemicals, yet unlike tetrahydrocannabinol, or THC, it does not produce a high.

The committee's recommendation was delivered after reviewing data from the drug's maker, GW Pharmaceuticals PLC, a UK-based biopharmaceutical company.

Epidiolex, GW's lead cannabinoid product candidate, was developed for severe, early-onset epilepsy syndromes, including Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life; Lennox-Gastaut syndrome, a type of epilepsy with multiple types of seizures; and tuberous sclerosis complex and infantile spasms, both of which begin in infancy and cause a sudden stiffening of the body, arms and legs with the head bent forward.

One-third of Americans who have epilepsy have found no therapies that will control their seizures, according to the Epilepsy Foundation. This represents about 1 million families.

Though FDA approval would limit use of the drug to epilepsy patients, doctors would have the option to prescribe it "off-label" for other uses.

Shauna Garris, a pharmacist, pharmacy clinical specialist and adjunct assistant professor at the University of North Carolina's Eshelman School of Pharmacy, said she would be surprised if Epidiolex does not get full approval from the FDA. Garris was not involved in the development of the drug and has not used it in her own clinical practice.

Still, she said, "there's so much publicity and so much hype" surrounding the product, she's not sure it will live up to "all that hype."

Epidiolex is effective, she said, working somewhere between "fairly" and "very well."

"There have been side effects associated with it, and it appears a lot of the side effects were in conjunction with other medications, which is a concern, because most of those patients are on other medications," Garris said. There are likely to be drug interactions, she said, but "that's not uncommon for antiepileptic medications."

"Most of our antiepileptic medications have terrible side effects and interact with each other," she said. Still, this may impact potential efficacy.

In a statement, GW Pharmaceuticals said that two experimental clinical trials, one in Dravet syndrome and one in Lennox-Gastaut syndrome, showed "significantly greater reductions" in certain seizure types for patients taking Epidiolex compared with those taking a placebo.

During the public hearing at Thursday's advisory committee meeting, 16-year-old Sam Vogelstein of Berkeley, California, described himself as "the first person to try Epidiolex for epilepsy." He said he was not paid by the company to speak Thursday.

"I had seizures for 10 years," he said. "My parents tell me there were times I had seizures 100 times a day." He began Epidiolex five years ago. "I've been seizure-free for more than two years now. It changed my life."

Damage to the liver, which metabolizes drugs and detoxifies chemicals, is an important consideration during the recommendation process of any medicine.

Dr. Lara Dimick-Santos, a clinical reviewer in the FDA's Office of Drug Evaluation, reviewed the liver safety report and concluded that there were "no cases of severe liver injury" and "no deaths related with liver injury." She suggested, though, that some patients might experience some form of "unknown of chronic liver injury." Such a "smoldering inflammatory response" could "potentially cause a problem for patients further down the line."

Katherine Bonson, a member of the FDA's Pharmacologist Controlled Substance Staff, assessed the abuse potential for cannabidiol after looking at both animal and human experimental data. "Overall conclusion, preclinical data do not provide signals that CBD has abuse potential," she said.

West Lafayette
Clear
72° wxIcon
Hi: 90° Lo: 67°
Feels Like: 72°
Kokomo
Clear
72° wxIcon
Hi: 90° Lo: 66°
Feels Like: 72°
Rensselaer
Clear
68° wxIcon
Hi: 87° Lo: 63°
Feels Like: 68°
Fowler
Clear
68° wxIcon
Hi: 89° Lo: 65°
Feels Like: 68°
Williamsport
Clear
71° wxIcon
Hi: 89° Lo: 66°
Feels Like: 71°
Crawfordsville
Overcast
68° wxIcon
Hi: 88° Lo: 67°
Feels Like: 68°
Frankfort
Broken Clouds
74° wxIcon
Hi: 89° Lo: 67°
Feels Like: 74°
Delphi
Clear
71° wxIcon
Hi: 91° Lo: 65°
Feels Like: 71°
Monticello
Clear
71° wxIcon
Hi: 93° Lo: 65°
Feels Like: 71°
Logansport
Clear
70° wxIcon
Hi: 91° Lo: 66°
Feels Like: 70°
WLFI Radar
WLFI Temps
WLFI Planner

Indiana Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 46387

Reported Deaths: 2662
CountyConfirmedDeaths
Marion11434680
Lake4985241
Elkhart313343
Allen2695117
St. Joseph185766
Cass16369
Hamilton1502100
Hendricks1371100
Johnson1244118
Porter69037
Tippecanoe6598
Madison64363
Clark62744
Bartholomew58044
Howard55057
LaPorte54125
Kosciusko5003
LaGrange4646
Jackson4583
Vanderburgh4576
Noble45128
Delaware42949
Boone42743
Hancock42535
Marshall4183
Shelby41825
Floyd37044
Morgan32331
Montgomery29020
Grant28726
Clinton2812
Monroe26328
Dubois2616
White25910
Decatur24732
Henry23615
Lawrence23624
Vigo2278
Harrison20822
Warrick20729
Dearborn20622
Greene18432
Miami1802
Jennings16911
Putnam1658
DeKalb1594
Scott1557
Daviess13916
Orange13323
Wayne1296
Franklin1248
Steuben1242
Perry1239
Ripley1148
Jasper1132
Carroll1092
Wabash1092
Fayette967
Newton9610
Whitley814
Randolph774
Starke773
Huntington702
Wells681
Jay670
Fulton661
Jefferson661
Washington651
Knox630
Pulaski621
Clay594
Rush563
Benton480
Adams471
Gibson462
Owen451
Sullivan441
Brown381
Blackford372
Posey360
Spencer331
Tipton301
Crawford290
Fountain292
Switzerland260
Martin220
Parke220
Ohio140
Warren141
Union130
Vermillion130
Pike80
Unassigned0193

COVID-19 Important links and resources

As the spread of COVID-19, or as it's more commonly known as the coronavirus continues, this page will serve as your one-stop for the resources you need to stay informed and to keep you and your family safe. CLICK HERE

Closings related to the prevention of the COVID-19 can be found on our Closings page.

Community Events